RxDoctor Payments Data

Esteban Escolar, MD

Cardiovascular Disease · Miami Beach, FLNPI 1891965158

Payments from drug & device makers

$1,958in general payments, 2019–2025

Across 39 payments — averaging $50.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals, Ltd$900
  • Medtronic$411
  • Abbott$184
  • Boston Scientific$176
  • Johnson & Johnson$58
  • Edwards Lifesciences$39
  • plus $190 from 9 others

What the payments were for

  • Food & beverage$1,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,958 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$246,084
Medicare patients
594
Services billed
2,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$156,685
EntrestoSacubitril/Valsartan83$115,372
XareltoRivaroxaban42$51,634
Repatha SureclickEvolocumab25$28,895
FarxigaDapagliflozin Propanediol13$11,470
BrilintaTicagrelor18$10,381
Ezetimibe145$2,524
Rosuvastatin Calcium128$1,456
Metoprolol Succinate168$1,450
Atorvastatin Calcium188$1,313
Ranolazine ErRanolazine11$1,279
ClopidogrelClopidogrel Bisulfate98$1,127
Chlorthalidone49$877
Amlodipine Besylate146$809
Losartan Potassium116$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$156,685139 claims
NovartisEntresto$18$115,37283 claims
Johnson & JohnsonXarelto$58$51,63442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →